SC13 是一种具有口服活性和选择性的 FEN1 抑制剂及 μ 阿片受体 (MOR) 激活剂,可损伤 DNA 损伤修复过程并诱导癌细胞凋亡 (apoptosis),同时可激活 cGAS-STING 信号通路、增加趋化因子分泌并促进 CAR-T 细胞向实体瘤部位浸润,因此可用于实体瘤与疼痛相关的研究。
产品编号: MS-D72473 CAS No.: 2839142-69-5 分子式: C26H30N2O5 分子量: 450.53
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

SC13 是一种具有口服活性和选择性的 FEN1 抑制剂及 μ 阿片受体 (MOR) 激活剂,可损伤 DNA 损伤修复过程并诱导癌细胞凋亡 (apoptosis),同时可激活 cGAS-STING 信号通路、增加趋化因子分泌并促进 CAR-T 细胞向实体瘤部位浸润,因此可用于实体瘤与疼痛相关的研究。

生物实验数据

生物活性 SC13 is an orally active and selective FEN1 inhibitor and μ opioid receptor (MOR) activator that impairs DNA damage repair and induces cancer cell apoptosis, while also activating the cGAS-STING signaling pathway, increasing chemokine secretion, and promoting CAR-T cell infiltration into solid tumors, making it useful for research on solid tumors and pain-related conditions.
IC50 & Target

μ Opioid Receptor/MOR

 

体外研究
(In Vitro)

SC13 (20 μM;48 小时) 可诱导 HeLa、MCF-7 和 SKOV-3 人癌细胞中 DNA 双链断裂累积及细胞质双链 DNA 渗漏。
SC13 (20 μM;48 小时) 可激活 cGAS-STING 通路,并上调 HeLa、MCF-7 和 SKOV-3 人癌细胞中趋化因子 (CCL5、CXCL10) 及 IFN-β 的表达,该过程依赖于 STING 信号通路。
SC13 (20 μM;48 小时) 可诱导 HeLa、MCF-7 和 SKOV-3 细胞分泌趋化因子,进而通过依赖 TBK1 的机制促进 MSLN CAR-T 细胞迁移。
SC13 (20 μM;48 小时) 可诱导轻度 DNA 损伤,但不会损害 MSLN CAR-T 细胞的增殖、CAR 表达或细胞毒性功能。
SC13 可强效抑制表达人 μ-阿片受体的 HEK-T 细胞中 cAMP 的生成,其 EC50 为 7.25 nM。
SC13 在表达人 μ 阿片受体的 HTLA 细胞中招募 β-arrestin2,其效能较低 (EC50 = 11000 nM),功效中等。
SC13 在表达人 μ 阿片受体的细胞中作为 Gi-1 G 蛋白激活的部分激动剂,且相对于 DOR 和 KOR 对 MOR 具有高选择性。

Cell Proliferation Assay

Cell Line: HeLa, MCF-7, SKOV-3 human cancer cell lines
Concentration: 20 μM
Incubation Time: 48 h
Result: Upregulated γ-H2AX (a marker of DNA double-strand breaks) in HeLa, MCF-7, and SKOV-3 cells.
Increased cytoplasmic dsDNA leakage in these cell lines.

Real Time qPCR

Cell Line: HeLa, MCF-7, SKOV-3 human cancer cell lines
Concentration: 20 μM
Incubation Time: 48 h
Result: Activated the cGAS-STING pathway and increased chemokine (CCL5, CXCL10) and IFN-β expression, dependent on STING signalling.

Cell Migration Assay

Cell Line: MSLN CAR-T cells, HeLa, MCF-7, SKOV-3 human cancer cell lines
Concentration: 20 μM
Incubation Time: 48 h
Result: Significantly increased the number of migrating MSLN CAR-T cells compared to medium from vehicle-treated tumour cells; this effect was blocked by pre-treatment of tumour cells with the TBK1 inhibitor Amlexanox.
Increased secretion of CCL5 and CXCL10 in the supernatant of SC13-treated tumour cells.
体内研究
(In Vivo)

SC13 (5 mg/kg;腹腔注射;每隔 1 天 1 次,共 32 天) 可增强 MSLN CAR-T 细胞介导的 HeLa 异种移植瘤抗肿瘤效力,使肿瘤重量降低约 60%,瘤内 CD8+ T 细胞浸润增加约 168%,并提升瘤内 CCL5 和 CXCL10 水平,且未观察到器官毒性。
SC13 (1-15 mg/kg;皮下注射或口服;单次给药) 可在小鼠中产生 MOR 依赖性镇痛作用,其皮下注射 ED50 为 3.05 mg/kg,且经口服给药仍能维持药效。
SC13 (15 mg/kg;皮下注射;每日 1 次;连续 2 天) 不会诱导家鼠产生奖赏效应或烦躁情绪。
SC13 (15 mg/kg;皮下注射;单次给药) 不会抑制小鼠的胃肠推进运动。
SC13 (45 mg/kg;皮下注射;单次给药) 不会导致小鼠呼吸抑制或运动过度。

Animal Model: B-NDG (6 weeks old; injected 5 × 106 HeLa cells subcutaneously into the mice)
Dosage: 5 mg/kg
Administration: i.p.; every other day for 32 days
Result: Reduced mean tumour weight to ~0.2 g compared to ~0.5 g in CAR-T alone group.
Increased intratumoural CD8+ T-cell infiltration to 18.65% of tumour-infiltrating cells compared to 6.95% in CAR-T alone group.
Increased CD8 signal intensity ~4-fold compared to CAR-T alone group.
Elevated CCL5 fluorescence intensity ~3-fold compared to CAR-T alone group.
Elevated CXCL10 fluorescence intensity ~2-fold compared to CAR-T alone group.
Caused no significant change in mouse body weight.
Showed no exacerbated organ damage to heart, liver, spleen, lung, or kidney.
Animal Model: C57BL/6J mice (20-32 g)
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg; 15 mg/kg
Administration: s.c. or p.o.; single dose
Result: Produced dose-dependent antinociception.
Reached a maximum of ~30% MPE at 20 minutes post-administration with 1 mg/kg s.c..
Reached ~30% MPE at 20 minutes post-administration with 3 mg/kg s.c..
Reached 100% MPE at 20 minutes post-administration with 10 mg/kg s.c..
Achieved an ED50 of 3.05 mg/kg s.c. for antinociception.
Showed significantly reduced antinociception in MOR knockout mice, but remained intact in KOR knockout and DOR knockout mice.
Reached a peak of 87% MPE at 30 minutes post-administration with 10 mg/kg p.o..
Animal Model: C57BL/6J mice (20-32 g)
Dosage: 15 mg/kg
Administration: s.c.; daily; 2 days
Result: Produced no significant conditioned place preference or aversion.
Showed no statistically significant difference in time spent in the drug-paired compartment compared to pre-conditioning.
Animal Model: C57BL/6J mice (20-32 g)
Dosage: 15 mg/kg
Administration: s.c.; single dose
Result: Had no significant effect on gastrointestinal transit.
Resulted in charcoal traveling 30.8 cm, a value indistinguishable from saline-treated mice.
Animal Model: C57BL/6J mice (20-32 g)
Dosage: 45 mg/kg
Administration: s.c.; single dose
Result: Showed no statistically significant respiratory depression compared to vehicle.
Had breath rate comparable to vehicle/saline controls at all time points except 180 and 200 minutes, where it showed a slight increase.
Produced no significant hyperlocomotion.
Had ambulation distance indistinguishable from vehicle/saline controls at all time points.

化学信息

分子量 450.53
分子式 C26H30N2O5
CAS No. 2839142-69-5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础